Pre-Assessment

Please enable JavaScript in your browser to complete this form.
Name
1. Which of the following best represents your profession?
2. A 68-year-old patient with symptomatic high-risk MF has a platelet count of ≥ 50 x 109/L with anemia and splenomegaly but is not a candidate for a allogeneic transplant. Which of the following treatment options would you discuss as the most appropriate for this patient?
3. Which of the following symptoms from the Myeloproliferative Neoplasm Symptom assessment form would you discuss with your patient through shared decision making to help alleviate burden on quality of life?
4. A patient with MF is in clinic for evaluation and tells you that they have experienced cytopenias during the course of the disease and it has had a profound impact on their quality of life. They experienced anemia early in the course of their disease. What may be the primary cause of concern for this patient that you should educate and discuss with them today?
5. A 59-year-old patient with MF has experienced significant spleen enlargement, symptomatic anemia, thrombocytopenia (platelet count 31 x 109/L) as well as debilitating symptoms such as fatigue, night sweats, and bone pain, which considerably impact his quality of life. You are discussing switching his current treatment to pacritinib. What would you tell him he can likely expect regarding this treatment and his quality of life?
6. How confident are you in monitoring/mitigating treatment-related adverse events of JAK inhibitors?
Scroll to Top